Should we take high-density lipoprotein cholesterol levels at face value?

American Journal of Cardiovascular Drugs

Volumn 10, Issue 1, 2010, Pages 1-3

  Leite, Jose Oyama ^a   Fernandez, Maria Luz ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Atherosclerosis, prevention; Atherosclerosis, treatment; Cardiovascular disorders, prevention; Cholesterol ester transfer protein inhibitors, therapeutic use; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; NOTE; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 77149170050     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11319590-000000000-00000     Document Type: Note

References (25)

1. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62: 707-714
2. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High -Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 19-22L
3. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009; 35: 98-104
4. Murphy AJ, Chin-Dusting JP, Sviridov D, et al. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009; 16: 667-675
5. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857
6. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable lowdensity lipoprotein cholesterol. Am J Cardiol 1993; 71: 45-52
7. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT. A randomized controlled trial. JAMA 2001; 285: 1585-1591
8. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-853
9. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300
10. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-1682
11. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-1630
12. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370: 153-160
13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122
14. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465-1473
15. Joy TR, Hegele RA. The failure of torcetrapib: what have we learned? Br J Pharmacol 2008; 154: 1379-1381
16. Kozarsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20: 721-727
17. Gualandri V, Franceschini G, Sirtori CR, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985; 37: 1083-1097
18. Sirtori CR, Calabresi L, FranceschiniG, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103: 1949-1954
19. Franceschini G, Vecchio G, Gianfranceschi G, et al. Apolipoprotein AIMilano: accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 1985; 260: 16321-16325
20. Ueda Y, Royer L, Gong E, et al. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 1999; 274: 7165-7171
21. Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387: 414-417
22. Arai T, Wang N, Bezouevski M, et al. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999; 274: 2366-2371
23. Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997; 94: 12610-12615
24. Jin FY, Kamanna VS, Chuang MY, et al. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler Thromb Vasc Biol 1996; 16: 1052-1062
25. Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-1712